Global /Australia /Healthcare /Biotechnology /AGN

Argenica Therapeutics Ltd.

AGN

• ASX: AGN • Delayed

0.1750AUD 0%

0.1238 USD

As of 18 June 2026, Argenica Therapeutics Ltd. has a market cap of $15.83M USD, ranking #38659 globally and #1167 in Australia. It ranks #3453 in the Healthcare sector, and #676 in the Biotechnology industry.

Global Rank

38659

Country Rank

1167

Sector Rank

3453

Industry Rank

676

Key Stats

Market Cap

$15.83MUSD

22.48M AUD

Enterprise Value

$12.34MUSD

17.44M AUD

Revenue (TTM)

$708.83KUSD

1.01M AUD

Net Income (TTM)

-$6.9MUSD

-9.8M AUD

PS Ratio

22.3

PB Ratio

6.5

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Liz Dallimore open_in_new

Founded

2019

Website

argenica.com.au open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-4.3%	2.9%	-31%	-39%	-41%	-74%	-60%	-45%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	AGN Argenica Therapeutics Ltd Ordinary Shares ISIN: AU0000150328 Shares Out.: Shares Outstanding: 128.457M¹ Shares Float: 111.337M² TV: TradingView: ASX: AGN SA: Stock Analysis: ASX: AGN YF: Yahoo Finance: AGN.AX GF: Google Finance: ASX: AGN BA: Barron's: AGN MS: Morningstar: XASX: AGN	0.1750 AUD	TV: TradingView: ASX: AGN SA: Stock Analysis: ASX: AGN YF: Yahoo Finance: AGN.AX GF: Google Finance: ASX: AGN BA: Barron's: AGN MS: Morningstar: XASX: AGN

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Argenica Therapeutics Ltd.

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.44B 60.27B AUD 268K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 23K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.03B 2.88B AUD 13K%	-	Australia
PolyNovo Ltd. ASX: PNV	$491.34M 697.75M AUD 3K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 795%	-	Australia
Immutep Ltd. ASX: IMM	$65.38M 92.84M AUD 313%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 1M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 1M%	19.0	United States
argenx SE EBR: ARGX	$47.76B 41.39B EUR 302K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.7B 68.19T KRW 282K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.29B 33.71B CHF 267K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.03B 42.76T KRW 177K%	43.8	South Korea

chevron_leftBack